Emergent BioSolutions and the University of Oxford form Joint Venture to Develop an Advanced Tuberculosis Vaccine with Funding from Wellcome Trust Sanger Institute and Aeras Global TB Vaccine Foundation

OXFORD, England & ROCKVILLE, Md.--(BUSINESS WIRE)--The University of Oxford and Emergent BioSolutions Inc. (NYSE:EBS) announced today that they have formed a joint venture, The Oxford-Emergent Tuberculosis Consortium Ltd. (the “Consortium”), to further develop MVA85A, the world’s most clinically advanced vaccine candidate for the prevention of tuberculosis. The University of Oxford, through its technology transfer office, Isis Innovation Limited, has exclusively licensed the MVA85A tuberculosis vaccine candidate and related technology to the Consortium.